Hydroxyapatite-based Carriers for Tumor Targeting Therapy

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2023 Jun 5

PMID 37274393

Authors

Gongming Qian

Lingya Xiong

Qing Ye

Affiliations

Soon will be listed here.

Abstract

At present, targeted drug delivery is regarded as the most effective means of tumor treatment, overcoming the lack of conventional chemotherapeutics that are difficult to reach or enter into cancer cells. Hydroxyapatite (HAP) is the main component of biological hard tissue, which can be regarded as a suitable drug carrier due to its biocompatibility, nontoxicity, biodegradation, and absorbability. This review focuses on the cutting edge of HAP as a drug carrier in targeted drug delivery systems. HAP-based carriers can be obtained by doping, modification, and combination, which benefit to improve the loading efficiency of drugs and the response sensitivity of the microenvironment in the synthesis process. The drug adsorbed or loaded on HAP-based carriers can achieve targeted drug delivery and precise treatment through the guidance of the microenvironment and the stimulation of the response. In addition, HAP-based drug carriers can improve the cellular uptake rate of drugs to achieve a higher treatment effect. These advantages revealed the promising potential of HAP-based carriers from the perspective of targeted drug delivery for tumor treatment.

References

Li H, Sun X, Li Y, Li B, Liang C, Wang H . Preparation and properties of carbon nanotube (Fe)/hydroxyapatite composite as magnetic targeted drug delivery carrier. Mater Sci Eng C Mater Biol Appl. 2019; 97:222-229. DOI: 10.1016/j.msec.2018.11.042. View

Zhou C, Hong Y, Zhang X . Applications of nanostructured calcium phosphate in tissue engineering. Biomater Sci. 2020; 1(10):1012-1028. DOI: 10.1039/c3bm60058k. View

Sadat-Shojai M, Atai M, Nodehi A, Nasiri Khanlar L . Hydroxyapatite nanorods as novel fillers for improving the properties of dental adhesives: Synthesis and application. Dent Mater. 2010; 26(5):471-82. DOI: 10.1016/j.dental.2010.01.005. View

Turlybekuly A, Pogrebnjak A, Sukhodub L, Sukhodub L, Kistaubayeva A, Savitskaya I . Synthesis, characterization, in vitro biocompatibility and antibacterial properties study of nanocomposite materials based on hydroxyapatite-biphasic ZnO micro- and nanoparticles embedded in Alginate matrix. Mater Sci Eng C Mater Biol Appl. 2019; 104:109965. DOI: 10.1016/j.msec.2019.109965. View

Paradossi G, Cavalieri F, Chiessi E, Spagnoli C, Cowman M . Poly(vinyl alcohol) as versatile biomaterial for potential biomedical applications. J Mater Sci Mater Med. 2004; 14(8):687-91. DOI: 10.1023/a:1024907615244. View

Herrera-Alonso A, Ibarra-Alonso M, Esparza-Gonzalez S, Estrada-Flores S, Garcia-Cerda L, Martinez-Luevanos A . Biomimetic Growth of Hydroxyapatite on SiO Microspheres to Improve Its Biocompatibility and Gentamicin Loading Capacity. Materials (Basel). 2021; 14(22). PMC: 8621055. DOI: 10.3390/ma14226941. View

Tang Q, Zhu Y, Wu J, Chen F, Cao S . Calcium phosphate drug nanocarriers with ultrahigh and adjustable drug-loading capacity: One-step synthesis, in situ drug loading and prolonged drug release. Nanomedicine. 2011; 7(4):428-34. DOI: 10.1016/j.nano.2010.12.005. View

Behranvand N, Nasri F, Zolfaghari Emameh R, Khani P, Hosseini A, Garssen J . Chemotherapy: a double-edged sword in cancer treatment. Cancer Immunol Immunother. 2021; 71(3):507-526. PMC: 10992618. DOI: 10.1007/s00262-021-03013-3. View

Zhang S, Ma X, Sha D, Qian J, Yuan Y, Liu C . A novel strategy for tumor therapy: targeted, PAA-functionalized nano-hydroxyapatite nanomedicine. J Mater Chem B. 2020; 8(41):9589-9600. DOI: 10.1039/d0tb01603a. View

10.

Zhang C, Wang W, Liu T, Wu Y, Guo H, Wang P . Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy. Biomaterials. 2011; 33(7):2187-96. DOI: 10.1016/j.biomaterials.2011.11.045. View

11.

Yang L, Ning Q, Tang S . Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment. J Immunol Res. 2022; 2022:8052212. PMC: 8956433. DOI: 10.1155/2022/8052212. View

12.

Mohd Puad N, Koshy P, Abdullah H, Idris M, Lee T . Syntheses of hydroxyapatite from natural sources. Heliyon. 2019; 5(5):e01588. PMC: 6507053. DOI: 10.1016/j.heliyon.2019.e01588. View

13.

Das R, Gandhi V, Singh B, Kunwar A . Passive and Active Drug Targeting: Role of Nanocarriers in Rational Design of Anticancer Formulations. Curr Pharm Des. 2019; 25(28):3034-3056. DOI: 10.2174/1381612825666190830155319. View

14.

Lee M, Seonwoo H, Jang K, Pandey S, Lim J, Park S . Development of novel gene carrier using modified nano hydroxyapatite derived from equine bone for osteogenic differentiation of dental pulp stem cells. Bioact Mater. 2021; 6(9):2742-2751. PMC: 7895645. DOI: 10.1016/j.bioactmat.2021.01.020. View

15.

Liu Y, Bhattarai P, Dai Z, Chen X . Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer. Chem Soc Rev. 2018; 48(7):2053-2108. PMC: 6437026. DOI: 10.1039/c8cs00618k. View

16.

Uskokovic V, Desai T . In vitro analysis of nanoparticulate hydroxyapatite/chitosan composites as potential drug delivery platforms for the sustained release of antibiotics in the treatment of osteomyelitis. J Pharm Sci. 2014; 103(2):567-79. PMC: 4045008. DOI: 10.1002/jps.23824. View

17.

Sang R, Chen M, Yang Y, Li Y, Shi J, Deng Y . HAp@GO drug delivery vehicle with dual-stimuli-triggered drug release property and efficient synergistic therapy function against cancer. J Biomed Mater Res A. 2019; 107(10):2296-2309. DOI: 10.1002/jbm.a.36738. View

18.

Song Z, Liu Y, Shi J, Ma T, Zhang Z, Ma H . Hydroxyapatite/mesoporous silica coated gold nanorods with improved degradability as a multi-responsive drug delivery platform. Mater Sci Eng C Mater Biol Appl. 2017; 83:90-98. DOI: 10.1016/j.msec.2017.11.012. View

19.

Nadra I, Mason J, Philippidis P, Florey O, Smythe C, McCarthy G . Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways: a vicious cycle of inflammation and arterial calcification?. Circ Res. 2005; 96(12):1248-56. DOI: 10.1161/01.RES.0000171451.88616.c2. View

20.

Liu Y, Raina D, Sebastian S, Nagesh H, Isaksson H, Engellau J . Sustained and controlled delivery of doxorubicin from an in-situ setting biphasic hydroxyapatite carrier for local treatment of a highly proliferative human osteosarcoma. Acta Biomater. 2021; 131:555-571. DOI: 10.1016/j.actbio.2021.07.016. View